Acumen Pharmaceuticals, Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Acumen Pharmaceuticals, Inc. (ABOS) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $6.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-06-30 was $0.00.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2026-03-31 was $6.00K, a 100.00% increase year-over-year.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $42.00K.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was $14.00K, a 85.26% decline year-over-year.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $59.00K, a 39.18% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $97.00K, a 781.82% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $11.00K.
- Acumen Pharmaceuticals, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $0.00.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.00K 10-Q · filed 2026-08-12 | $48.00K derived: sum of 3 quarters · filed 2026-08-12 | $62.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-12 | $48.00K derived: sum of 2 quarters · filed 2026-05-12 | $62.00K derived: sum of 3 quarters · filed 2026-05-12 | $62.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $56.00K derived: sum of 2 quarters · filed 2026-03-26 | $56.00K derived: sum of 3 quarters · filed 2026-08-12 | $59.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.00K derived: sum of 2 quarters · filed 2026-08-12 | $17.00K 10-Q · filed 2025-11-12 | $17.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.00K 10-Q · filed 2026-08-12 | $3.00K derived: sum of 3 quarters · filed 2026-08-12 | $98.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.00K 10-Q · filed 2026-05-12 | $3.00K derived: sum of 2 quarters · filed 2026-05-12 | $98.00K derived: sum of 3 quarters · filed 2026-05-12 | $98.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $95.00K derived: sum of 2 quarters · filed 2026-03-26 | $95.00K derived: sum of 3 quarters · filed 2026-03-26 | $97.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $95.00K derived: sum of 2 quarters · filed 2025-11-12 | $97.00K 10-Q · filed 2025-11-12 | $108.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.00K 10-Q · filed 2025-08-12 | $13.00K derived: sum of 3 quarters · filed 2025-08-12 | $13.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-13 | $13.00K derived: sum of 2 quarters · filed 2025-05-13 | $13.00K derived: sum of 3 quarters · filed 2025-05-13 | $13.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $11.00K derived: sum of 2 quarters · filed 2025-03-27 | $11.00K derived: sum of 3 quarters · filed 2025-03-27 | $11.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |